newsroom.csl48 分钟
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent ...
ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...